153 related articles for article (PubMed ID: 9174621)
81. Macrocyclic hydroxamate inhibitors of matrix metalloproteinases and TNF-alpha production.
Cherney RJ; Wang L; Meyer DT; Xue CB; Arner EC; Copeland RA; Covington MB; Hardman KD; Wasserman ZR; Jaffee BD; Decicco CP
Bioorg Med Chem Lett; 1999 May; 9(9):1279-84. PubMed ID: 10340614
[TBL] [Abstract][Full Text] [Related]
82. Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 1: Structure-based design of novel acetylenic P1' groups.
Chen JM; Jin G; Sung A; Levin JI
Bioorg Med Chem Lett; 2002 Apr; 12(8):1195-8. PubMed ID: 11934587
[TBL] [Abstract][Full Text] [Related]
83. Tumor necrosis factor alpha converting enzyme: an encouraging target for various inflammatory disorders.
Bahia MS; Silakari O
Chem Biol Drug Des; 2010 May; 75(5):415-43. PubMed ID: 20486929
[TBL] [Abstract][Full Text] [Related]
84. A continuous fluorimetric assay for tumor necrosis factor-alpha converting enzyme.
Jin G; Huang X; Black R; Wolfson M; Rauch C; McGregor H; Ellestad G; Cowling R
Anal Biochem; 2002 Mar; 302(2):269-75. PubMed ID: 11878807
[TBL] [Abstract][Full Text] [Related]
85. In vitro processing of human tumor necrosis factor-alpha.
Robache-Gallea S; Morand V; Bruneau JM; Schoot B; Tagat E; Réalo E; Chouaib S; Roman-Roman S
J Biol Chem; 1995 Oct; 270(40):23688-92. PubMed ID: 7559538
[TBL] [Abstract][Full Text] [Related]
86. Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Sheppeck JE; Gilmore JL; Tebben A; Xue CB; Liu RQ; Decicco CP; Duan JJ
Bioorg Med Chem Lett; 2007 May; 17(10):2769-74. PubMed ID: 17368021
[TBL] [Abstract][Full Text] [Related]
87. Identification of a selectivity determinant for inhibition of tumor necrosis factor-alpha converting enzyme by comparative modeling.
Wasserman ZR; Duan JJ; Voss ME; Xue CB; Cherney RJ; Nelson DJ; Hardman KD; Decicco CP
Chem Biol; 2003 Mar; 10(3):215-23. PubMed ID: 12670535
[TBL] [Abstract][Full Text] [Related]
88. Chemotactic agents induce IL-6Ralpha shedding from polymorphonuclear cells: involvement of a metalloproteinase of the TNF-alpha-converting enzyme (TACE) type.
Marin V; Montero-Julian F; Grès S; Bongrand P; Farnarier C; Kaplanski G
Eur J Immunol; 2002 Oct; 32(10):2965-70. PubMed ID: 12355450
[TBL] [Abstract][Full Text] [Related]
89. Matrix metalloproteinases and processing of pro-TNF-alpha.
Gearing AJ; Beckett P; Christodoulou M; Churchill M; Clements JM; Crimmin M; Davidson AH; Drummond AH; Galloway WA; Gilbert R
J Leukoc Biol; 1995 May; 57(5):774-7. PubMed ID: 7759957
[TBL] [Abstract][Full Text] [Related]
90. Mechanism of three inhibitors of TACE in blocking the converting of pro-TNF alpha into sTNF alpha.
Wang Z; Wang Y; Zhu K; Guo L; Yang Y
J Huazhong Univ Sci Technolog Med Sci; 2003; 23(2):116-20. PubMed ID: 12973924
[TBL] [Abstract][Full Text] [Related]
91. Cleavage of pro-tumor necrosis factor alpha by ADAM metallopeptidase domain 17: a fluorescence-based protease assay cleaves its natural protein substrate.
Zhang C; Zheng L; Nurnberg J; Vacari BM; Zhou J; Wang Y
Anal Biochem; 2014 Jan; 445():14-9. PubMed ID: 24096196
[TBL] [Abstract][Full Text] [Related]
92. Genetic mapping of mouse tumor necrosis factor-alpha converting enzyme (TACE) to chromosome 12.
Yamazaki K; Mizui Y; Sagane K; Tanaka I
Genomics; 1998 Apr; 49(2):336-7. PubMed ID: 9598327
[No Abstract] [Full Text] [Related]
93. In pneumococcal meningitis a novel water-soluble inhibitor of matrix metalloproteinases and TNF-alpha converting enzyme attenuates seizures and injury of the cerebral cortex.
Meli DN; Loeffler JM; Baumann P; Neumann U; Buhl T; Leppert D; Leib SL
J Neuroimmunol; 2004 Jun; 151(1-2):6-11. PubMed ID: 15145598
[TBL] [Abstract][Full Text] [Related]
94. Further evidence for a common mechanism for shedding of cell surface proteins.
Müllberg J; Rauch CT; Wolfson MF; Castner B; Fitzner JN; Otten-Evans C; Mohler KM; Cosman D; Black RA
FEBS Lett; 1997 Jan; 401(2-3):235-8. PubMed ID: 9013894
[TBL] [Abstract][Full Text] [Related]
95. [The structural features and inhibitors of tumor necrosis factor-alpha converting enzyme].
Du ZY; Li XY; Ye QZ
Sheng Li Ke Xue Jin Zhan; 1999 Jul; 30(3):245-8. PubMed ID: 12532790
[No Abstract] [Full Text] [Related]
96. Structures of adamalysin II with peptidic inhibitors. Implications for the design of tumor necrosis factor alpha convertase inhibitors.
Gomis-Rüth FX; Meyer EF; Kress LF; Politi V
Protein Sci; 1998 Feb; 7(2):283-92. PubMed ID: 9521103
[TBL] [Abstract][Full Text] [Related]
97. Cerebral ischemia, matrix metalloproteinases, and TNF-alpha: MMP inhibitors may act not exclusively by reducing MMP activity.
Dittmar M; Kiourkenidis G; Horn M; Bollwein S; Bernhardt G
Stroke; 2004 Jul; 35(7):e338-40; author reply e338-40. PubMed ID: 15192238
[No Abstract] [Full Text] [Related]
98. TNF-alpha-converting enzyme activity in colonic biopsy specimens from patients with inflammatory bowel disease revealed by mRNA and in vitro assay.
Føgh P; Ellervik C; Saermark T; Brynskov J
Ann N Y Acad Sci; 1999 Jun; 878():692-5. PubMed ID: 10415810
[No Abstract] [Full Text] [Related]
99. N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitution.
Musso DL; Andersen MW; Andrews RC; Austin R; Beaudet EJ; Becherer JD; Bubacz DG; Bickett DM; Chan JH; Conway JG; Cowan DJ; Gaul MD; Glennon KC; Hedeen KM; Lambert MH; Leesnitzer MA; McDougald DL; Mitchell JL; Moss ML; Rabinowitz MH; Rizzolio MC; Schaller LT; Stanford JB; Tippin T; Warner JR; Whitesell LG; Wiethe RW
Bioorg Med Chem Lett; 2001 Aug; 11(16):2147-51. PubMed ID: 11514157
[TBL] [Abstract][Full Text] [Related]
100. BMS-561392. Bristol-Myers Squibb.
Grootveld M; McDermott MF
Curr Opin Investig Drugs; 2003 May; 4(5):598-602. PubMed ID: 12833656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
